| Ident. | Authors (with country if any) | Title |
|---|
| 000325 (2013) |
Daniel E. Furst [États-Unis] ; Edward Clark Keystone [Canada] ; Alexander K. So [États-Unis, Canada, Allemagne, Pays-Bas, Italie, Royaume-Uni, Autriche] ; Jürgen Braun [Allemagne] ; Ferry C. Breedveld [Pays-Bas] ; Gerd R. Burmester [Italie] ; Fabrizio De Benedetti [Allemagne] ; Thomas Dörner [Allemagne] ; Paul Emery [Royaume-Uni] ; Roy Fleischmann [États-Unis] ; Allan Gibofsky [États-Unis] ; J R Kalden [Allemagne] ; Arthur Kavanaugh [États-Unis] ; Bruce Kirkham [Royaume-Uni] ; Philip Mease [États-Unis] ; A. Rubbert-Roth [Allemagne] ; Joachim Sieper [Allemagne] ; Nora G. Singer [États-Unis] ; Josef S. Smolen [Autriche] ; Piet L C M. Van Riel [Pays-Bas] ; Michael H. Weisman [États-Unis] ; Kevin L. Winthrop [États-Unis] | Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012 |
| 000326 (2013) |
Edith Villeneuve [Canada] ; Boulos Haraoui [Canada] | Uncoupling of disease activity and structural damage. Does it matter clinically? |
| 000333 (2013) |
Daniel Aletaha [Autriche] ; Farideh Alasti [Autriche] ; Josef S. Smolen [Autriche] | Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients |
| 000344 (2013) |
Maarten Boers [Pays-Bas] ; Lilian Van Tuyl [Pays-Bas] ; Marianne Van Den Broek [Pays-Bas] ; Piet J. Kostense [Pays-Bas] ; Cornelia F. Allaart [Pays-Bas] | Meta-analysis suggests that intensive non-biological combination therapy with step-down prednisolone (COBRA strategy) may also ‘disconnect’ disease activity and damage in rheumatoid arthritis |
| 000346 (2013) |
C. Malattia [Italie] ; A. Consolaro [Italie] ; S. Pederzoli [Italie] ; A. Madeo [Italie] ; A. Pistorio [Italie] ; M. Mazzoni [Italie] ; C. Mattiuz [Italie] ; Gm Magnano [Italie] ; S. Viola [Italie] ; A. Buoncompagni [Italie] ; E. Palmisani [Italie] ; R. Hasija [Italie] ; N. Ruperto [Italie] ; A. Ravelli [Italie] ; A. Martini [Italie] | MRI versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in juvenile idiopathic arthritis |
| 000347 (2013) |
Charles Peterfy [États-Unis] ; Mikkel Stergaard [Danemark] ; Philip G. Conaghan [Royaume-Uni] | MRI comes of age in RA clinical trials |
| 000358 (2013) |
Tsutomu Takeuchi [Japon] ; Masayoshi Harigai [Japon] ; Yoshiya Tanaka [Japon] ; Hisashi Yamanaka [Japon] ; Naoki Ishiguro [Japon] ; Kazuhiko Yamamoto [Japon] ; Nobuyuki Miyasaka [Japon] ; Takao Koike [Japon] ; Minoru Kanazawa [Japon] ; Takuya Oba [Japon] ; Toru Yoshinari [Japon] ; Daniel Baker [États-Unis] | Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks |
| 000369 (2013) |
Monika M. Schoels [Autriche] ; Désirée Van Der Heijde [Pays-Bas] ; Ferdinand C. Breedveld [Pays-Bas] ; Gerd R. Burmester [Allemagne] ; Maxime Dougados [France] ; Paul Emery [Royaume-Uni] ; Gianfranco Ferraccioli [Italie] ; Cem Gabay [Suisse] ; Allan Gibofsky [États-Unis] ; Juan Jesus Gomez-Reino ; Graeme Jones [Australie] ; Tore K. Kvien [Norvège] ; Miho M. Murikama [Japon] ; Norihiro Nishimoto [Japon] ; Josef S. Smolen [Autriche] | Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement |
| 000370 (2013) |
Paul Emery [Royaume-Uni] ; Anthony Sebba [États-Unis] ; Tom W J. Huizinga [Pays-Bas] | Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis |
| 000372 (2013) |
Maxime Dougados [France] ; Karsten Kissel [Suisse] ; Tom Sheeran [Royaume-Uni] ; Paul P. Tak [Pays-Bas] ; Philip G. Conaghan [Royaume-Uni] ; Emilio Martín Mola [Espagne] ; Georg Schett [Allemagne] ; Howard Amital [Israël] ; Federico Navarro-Sarabia [Espagne] ; Antony Hou [États-Unis] ; Corrado Bernasconi [Suisse] ; Twj Huizinga [Pays-Bas] | Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY) |
| 000491 (2013) |
K. Kume ; K. Amano ; S. Yamada ; T. Kanazawa ; H. Ohta ; K. Hatta [Japon] | THU0211 Combination of Intra-Articular Steroid Injection and Etanercept More Effective Than Etanercept in Rapid Radiographic Progression Patients with Rheumatoid Arthritis: A Randomized, Open Label, X Ray Reader Blinded Study |
| 000515 (2013) |
B. Möller [Suisse] ; A. Scherer [Suisse] ; P. M. Villiger [Suisse] ; A. Finckh [Suisse] | THU0129 Anemia Adds Information to Predict Radiographic Progression of Erosions on All Levels Levels of Clinically Assessed Disease Activity |
| 000520 (2013) |
A. Pfeil ; J. Böttcher [Allemagne] ; P. Oelzner ; G. Wolf | THU0123 Periarticular Demineralization as Measured by Digital X-Ray Radiogrammetry in Patients with Rheumatoid Arthritis – A Meta-Analysis |
| 000522 (2013) |
A. Novikov ; E. N. Alexandrova ; A. N. Gerasimov [Russie] ; A. S. Avdeeva ; G. V. Lukina ; Y. A. Sigidin ; T. V. Popkova ; E. Y. Panasyuk ; E. L. Nasonov | THU0122 Multi-Biomarker Scores as Predictors of Response to Biologic Therapies in Rheumatoid Arthritis |
| 000524 (2013) |
A. Okada ; A. Kawakami ; T. Fukuda ; T. Hidaka ; T. Ishii ; Y. Ueki ; T. Kodera ; M. Nakashima ; Y. Takahashi ; S. Honda ; Y. Horai ; T. Koga ; R. Watanabe ; H. Okuno ; K. Eguchi [Japon] | THU0121 Characteristic of the Japanese Patients with Rheumatoid Arthritis (RA) of Rapid Radiographic Progression (RRP) Treated with Synthetic Disease Modifying Anti-Rheumatic Drugs (DMARDS) in Daily Practice: A Large-Scale Prospective Longitudinal Cohort Study |
| 000525 (2013) |
I. Klein-Wieringa ; S. Andersen ; L. Herb- Van Toorn ; J. Kwekkeboom ; A. Helm- Van Mil ; I. Meulenbelt [Pays-Bas] ; T. Huizinga ; M. Kloppenburg ; R. Toes ; A. Ioan-Facsinay | THU0120 Do High Molecular Weight Adiponectin Levels Associate with Radiographic Progression in Rheumatoid Arthritis and Hand Osteoarthritis? |
| 000529 (2013) |
L. Alifrangis [Danemark] ; P. André [France] ; V. Pascal ; E. Bonnet [France] ; L. Radzikowski [Danemark] ; M. B. Petersen [Danemark] ; M. Bléry [France] | THU0110 Affinity and potency of the anti-NKG2A MAB NNC141-0100: Implications for mabel and dosing in the first-in-man trial in rheumatoid arthritis |
| 000530 (2013) |
K. Kume ; K. Amano ; K. Hatta ; H. Ohta [Japon] | THU0109 Treating to target ultrasound with clinical remission better effects than clinical remission in RRP |
| 000531 (2013) |
J. Ducreux [Belgique] ; A. Nzeusseu Toukap [Belgique] ; F. A. Houssiau [Belgique] ; P. Durez [Belgique] ; B. Lauwerys [Belgique] | THU0108 Global molecular effects of tocilizumab therapy in synovial biopsies of early RA patients |
| 000532 (2013) |
Y. Yonemoto ; K. Okamura ; K. Takeuchi ; M. Matsushita [Japon] ; T. Kaneko ; T. Kobayashi ; T. Aramaki [Japon] ; K. Takagishi | THU0094 Direct comparison of four biological agents in bio-naïve rheumatoid arthritis patients |
| 000533 (2013) |
M. Dougados [France] ; K. Kissel [Suisse] ; P. G. Conaghan [Royaume-Uni] ; E. Martin-Mola [Espagne] ; G. Schett [Allemagne] ; H. Amital [Israël] ; R. M. Xavier [Brésil] ; O. Troum [États-Unis] ; C. Bernasconi [Suisse] ; T. W. J. Huizinga [Pays-Bas] | THU0093 Clinical, radiographic, and immunogenic effects after 1 year of tocilizumab (TCZ)-based treatment strategy with and without methotrexate (MTX) in RA: The act-ray study |
